Deutsch English Français

Contact

EP2105501

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP2105501

EP2105501 - Novel immunotherapy against neuronal and brain tumors [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 12.08.2016 Database last updated on 03.10.2024
Most recent event Tooltip	03.11.2017	Change - lapse in a contracting state State(s) deleted from list of lapses: CY	published on 06.12.2017 [2017/49]
Applicant(s)	For all designated states Immatics Biotechnologies GmbH Paul-Ehrlich-Strasse 15 72076 Tübingen / DE
	[2009/40]
Inventor(s)	01 / Emmerich, Niels 2943 N. Lincoln Avenue, Unit 213 Chicago, IL 60657 / US
	02 / Singh, Harpreet Possartstr. 16 81679 München / DE
	03 / Schoor Oliver Charlottenstrasse 21 72070 Tübingen / DE
	04 / Hilf, Norbert Im Wengertacker 17 72138 Kirchentellinsfurt / DE
	05 / Weinschenk, Toni Im Morgenrain 15 73773 Aichwald / DE
	06 / Trautwein, Claudia Narzissenweg 4 42489 Wülfrath / DE
	07 / Walter, Steffen Steinenbergstrasse 2 72764 Reutlingen / DE
	[2014/01]
Former [2013/50]	01 / Emmerich, Niels 2943 N. Lincoln Avenue, Unit 213 Chicago, IL 60657 / US
	02 / Singh, Harpreet Possartstr. 16 81679 München / DE
	03 / Schoor Oliver Charlottenstrasse 21 72070 Tübingen / DE
	04 / Hilf, Norbert Im Wengertacker 17 72138 Kirchentellinsfurt / DE
	05 / Weinschenk, Toni Im Morgenrain 15 73773 Aichwald / DE
	06 / Trautwein, Claudia Narzissenweg 4 42489 Wülfrath / DE
	07 / Walter, Steffen Blumenstrasse 1 72411 Dusslingen / DE
Former [2013/43]	01 / Emmerich, Niels Schönbuchstrasse 34 72074 Tübingen-Bebenhausen / DE
	02 / Singh, Harpreet Bei den Pferdeställen 9 72072 Tübingen / DE
	03 / Schoor Oliver Charlottenstrasse 21 72070 Tübingen / DE
	04 / Hilf, Norbert Im Wengertacker 17 72138 Kirchentellinsfurt / DE
	05 / Weinschenk, Toni Im Morgenrain 15 73773 Aichwald / DE
	06 / Trautwein, Claudia Narzissenweg 4 42489 Wülfrath / DE
	07 / Walter, Steffen Blumenstrasse 1 72411 Dusslingen / DE
Former [2009/46]	01 / Emmerich, Niels Schönbuchstrasse 34 72074 Tübingen-Bebenhausen / DE
	02 / Singh, Harpreet Bei den Pferdeställen 9 72072 Tübingen / DE
	03 / Schoor Oliver Charlottenstrasse 21 72070 Tübingen / DE
	04 / Hilf, Norbert Im Wengertacker 17 72138 Kirchentellinsfurt / DE
	05 / Weinschenk, Toni Im Morgenrain 15 73773 Aichwald / DE
	06 / Trautwein, Claudia Nelkenweg 2 42489 Wülfrath / DE
	07 / Walter, Steffen Blumenstrasse 1 72411 Dusslingen / DE
Former [2009/40]	01 / Emmerich, Niels Schönbuchstrasse 34 72074 Tübingen-Bebenhausen / DE
	02 / Singh, Harpreet Bei den Pferdeställen 9 72072 Tübingen / DE
	03 / Schoor Oliver Charlottenstrasse 21 72070 Tübingen / DE
Representative(s)	Krauss, Jan Boehmert & Boehmert Anwaltspartnerschaft mbB Pettenkoferstrasse 22 80336 München / DE
	[N/P]
Former [2015/41]	Krauss, Jan Boehmert & Boehmert Anwaltspartnerschaft mbB Patentanwälte Rechtsanwälte Pettenkoferstrasse 20-22 80336 München / DE
Former [2009/40]	Krauss, Jan Forrester & Boehmert Pettenkoferstrasse 20-22 80336 München / DE
Application number, filing date	08005889.4	27.03.2008
	[2009/40]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP2105501
	Date:	30.09.2009
	Language:	EN
	[2009/40]
	Type:	B1 Patent specification
	No.:	EP2105501
	Date:	07.10.2015
	Language:	EN
	[2015/41]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	23.10.2008
Classification	IPC:	C12N9/16, C07K7/06, C07K7/08, A61K39/00, A61P35/00	[2009/40]
	CPC:	C07K14/4748 (EP); A61P35/00 (EP)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2015/41]
Former [2009/40]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
Extension states	AL	05.10.2009
	BA	05.10.2009
	MK	05.10.2009
	RS	05.10.2009
Title	German:	Neuartige Immuntherapie gegen Nerven- und Hirntumore	[2009/40]
	English:	Novel immunotherapy against neuronal and brain tumors	[2009/40]
	French:	Nouvelle immunothérapie pour le traitement de tumeurs neuronales et cérébrales	[2009/40]
Examination procedure	05.10.2009	Examination requested [2009/47]
	06.11.2009	Despatch of a communication from the examining division (Time limit: M04)
	08.03.2010	Reply to a communication from the examining division
	25.03.2010	Despatch of a communication from the examining division (Time limit: M04)
	26.07.2010	Reply to a communication from the examining division
	23.11.2010	Despatch of a communication from the examining division (Time limit: M04)
	04.04.2011	Reply to a communication from the examining division
	27.03.2012	Despatch of a communication from the examining division (Time limit: M04)
	19.04.2012	Reply to a communication from the examining division
	14.05.2012	Despatch of a communication from the examining division (Time limit: M04)
	13.09.2012	Reply to a communication from the examining division
	25.07.2014	Despatch of a communication from the examining division (Time limit: M04)
	26.08.2014	Reply to a communication from the examining division
	26.05.2015	Cancellation of oral proceeding that was planned for 26.06.2015
	09.06.2015	Communication of intention to grant the patent
	26.06.2015	Date of oral proceedings (cancelled)
	27.08.2015	Fee for grant paid
	27.08.2015	Fee for publishing/printing paid
	27.08.2015	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 06.11.2009
Opposition(s)	08.07.2016	No opposition filed within time limit [2016/37]
Fees paid	Renewal fee
	15.03.2010	Renewal fee patent year 03
	15.03.2011	Renewal fee patent year 04
	14.03.2012	Renewal fee patent year 05
	11.03.2013	Renewal fee patent year 06
	12.03.2014	Renewal fee patent year 07
	10.03.2015	Renewal fee patent year 08
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	deleted
	[2017/49]
Former [2016/50]	CY	27.03.2016
Former [2016/27]	deleted
Former [2016/25]	LV	07.10.2015
Documents cited:	Search	[X]WO0075339 (COLD SPRING HARBOR LAB [US], et al) [X] 1-9* Sequence 32 100% with present sequences 1, 2, 3 and 7; sequence 25 100% identical with present sequence 8. *;
		[DY]US2002146370 (MUELLER SABINE [US], et al) [DY] 1-18 * Abstract. *;
		[DY]US2003118585 (MULLER SABINE [US], et al) [DY] 1-18 * Abstract. *;
		[X]WO2005116051 (IMMATICS BIOTECHNOLOGIES GMBH [DE], et al) [X] 1-18 * Abstract; p. 21, sequence 35 100% identical with present sequence 8; claims. *;
		[DY] - MULHOLLAND PAUL J ET AL, "Genomic profiling identifies discrete deletions associated with translocations in glioblastoma multiforme.", CELL CYCLE (GEORGETOWN, TEX.) APR 2006, (200604), vol. 5, no. 7, ISSN 1551-4005, pages 783 - 791, XP002484251 [DY] 1-18 * Abstract. *
		[X] - "Ptprz1 protein (Fragment).", UniProt, (20010601), Database accession no. Q99LN6, URL: EBI, XP002484252 [X] 1-9 * Sequence 100% identical with present sequence 1. *
	Examination	WO2004085461
		- "Putative uncharacterized protein", UNIPROT, (20030301), Database accession no. Q8FID6, URL: EBI
		- Kenneth Murphy ET AL, "Janeway's Immunobiology", Janeway's Immunobiology, Taylor & Francis, (20080102), pages 129 - 132, ISBN 978-0-81-534123-9, XP055049307
		- GILLES GUICHARD ET AL, "Efficient Binding of Reduced Peptide Bond Pseudopeptides to Major Histocompatibility Complex Class I Molecule", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, US, vol. 270, no. 44, doi:10.1074/JBC.270.44.26057, ISSN 0021-9258, (19951103), pages 26057 - 26059, (19951103), XP008153807 DOI: http://dx.doi.org/10.1074/jbc.270.44.26057
	by applicant	US4440859
		US4530901
		US4582800
		US4677063
		US4678751
		US4704362
		US4710463
		US4757006
		US4766075
		US4810648
		US4897445
		WO9518145
		WO9726328
		US5849589
		US6406705
		US6455026
		US7060275
		WO2007028574
		EP1760088
		- NEUROL. MED. CHIR. (TOKYO, (1994), vol. 34, pages 91 - 94
		- NEUROL. MED. CHIR. (TOKYO, (1993), vol. 33, pages 425 - 458
		- NEUROPATHOLOGY, (1997), vol. 17, pages 186 - 188
		- MEZIERE ET AL., J. IMMUNOL., (1997), vol. 159, pages 3230 - 3237
		- Current Protocols In Protein Science, JOHN WILEY & SONS, pages 1995 - 2000
		- COHEN ET AL., PROC. NATL. ACAD. SCI. USA, (1972), vol. 69, page 2110
		- BEGGS, NATURE, (1978), vol. 275, pages 104 - 109
		- ALLISON AC, "The mode of action of immunological adjuvants", DEV BIOL STAND., (1998), vol. 92, pages 3 - 11, XP000961024
		- ALTMAN JD ET AL., "Phenotypic analysis of antigen-specific T lymphocytes", SCIENCE, (1996), vol. 274, doi:doi:10.1126/science.274.5284.94, pages 94 - 96, XP002135711 DOI: http://dx.doi.org/10.1126/science.274.5284.94
		- APPAY V ET AL., "Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide", EUR. J IMMUNOL., (2006), vol. 36, pages 1805 - 1814
		- ARIYAMA T ET AL., "Assignment of the human protein tyrosine phosphatase, receptor-type, zeta (PTPRZ) gene to chromosome band 7q31.3", CYTOGENET. CELL GENET., (1995), vol. 70, pages 52 - 54
		- BARNEA G ET AL., "Identification of a carbonic anhydrase-like domain in the extracellular region of RPTP gamma defines a new subfamily of receptor tyrosine phosphatases", MOL. CELL BIOL., (1993), vol. 13, pages 1497 - 1506
		- BOYTON RJ ET AL., "Glutamic acid decarboxylase T lymphocyte responses associated with susceptibility or resistance to type I diabetes: analysis in disease discordant human twins, non-obese diabetic mice and HLA-DQ transgenic mice", INT. IMMUNOL., (1998), vol. 10, doi:doi:10.1093/intimm/10.12.1765, pages 1765 - 1776, XP000978516 DOI: http://dx.doi.org/10.1093/intimm/10.12.1765
		- BRUCKDORFER T; MARDER 0; ALBERICIO F., "From production of peptides in milligram amounts for research to multi-ton quantities for drugs of the future", CURR PHARM BIOTECHNOL. FEB, (2004), vol. 5, no. 1, doi:doi:10.2174/1389201043489620, pages 29 - 43, XP009063837 DOI: http://dx.doi.org/10.2174/1389201043489620
		- BRUNSVIG PF ET AL., "Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer", CANCER IMMUNOL IMMUNOTHER., (2006), vol. 55, no. 12, doi:doi:10.1007/s00262-006-0145-7, pages 1553 - 1564, XP019422504 DOI: http://dx.doi.org/10.1007/s00262-006-0145-7
		- BURTON EC; PRADOS MD, "Malignant gliomas", CURR. TREAT. OPTIONS. ONCOL, (2000), vol. 1, pages 459 - 468, XP001147220
		- CHEEVER MA ET AL., "T-cell immunity to oncogenic proteins including mutated ras and chimeric bcr-abl", ANN N. Y. ACAD. SCI., (1993), vol. 690, pages 101 - 112
		- COLOMBETTI S ET AL., "Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target ofrapamycin", J IMMUNOL., (2006), vol. 176, pages 2730 - 2738
		- CRESSWELL P, "Assembly, transport, and function of MHC class II molecules", ANNU. REV. IMMUNOL., (1994), vol. 12, pages 259 - 293
		- DAZZI C ET AL., "A sequential chemo- radiotherapeutic treatment for patients with malignant gliomas: a phase II pilot study", ANTICANCER RES., (2000), vol. 20, pages 515 - 518
		- DENGJEL J ET AL., "Unexpected Abundance of HLA Class II Presented Peptides in Primary Renal Cell Carcinomas", CLIN CANCER RES., (2006), vol. 12, pages 4163 - 4170
		- DIX AR ET AL., "Immune defects observed in patients with primary malignant brain tumors", J NEUROIMMUNOL., (1999), vol. 100, pages 216 - 232
		- DUDLEY ME ET AL., "Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes", SCIENCE, (2002), vol. 298, doi:doi:10.1126/science.1076514, pages 850 - 854, XP009113075 DOI: http://dx.doi.org/10.1126/science.1076514
		- DUDLEY ME ET AL., "Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma", J. CLIN. ONCOL., (2005), vol. 23, doi:doi:10.1200/JCO.2005.00.240, pages 2346 - 2357, XP002433186 DOI: http://dx.doi.org/10.1200/JCO.2005.00.240
		- DUPUIS M ET AL., "Dendritic cells internalize vaccine adjuvant after intramuscular injection", CELL IMMUNOL., (1998), vol. 186, no. 1, doi:doi:10.1006/cimm.1998.1283, pages 18 - 27, XP029583042 DOI: http://dx.doi.org/10.1006/cimm.1998.1283
		- FALK,K. ET AL., "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules", NATURE, (1991), vol. 351, doi:doi:10.1038/351290a0, pages 290 - 296, XP000310533 DOI: http://dx.doi.org/10.1038/351290a0
		- FONG L ET AL., "Dendritic cells injected via different routes induce immunity in cancer patients", J. IMMUNOL., (2001), vol. 166, pages 4254 - 4259
		- FONG L ET AL., "Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy", PROC. NATL. ACAD. SCI. U. S. A, (2001), vol. 98, doi:doi:10.1073/pnas.141226398, pages 8809 - 8814, XP003001078 DOI: http://dx.doi.org/10.1073/pnas.141226398
		- GABRILOVICH DI; CUNNINGHAM HT; CARBONE DP, "IL-12 and mutant P53 peptide-pulsed dendritic cells for the specific immunotherapy of cancer", J IMMUNOTHER EMPHASIS TUMOR IMMUNOL., (1996), vol. 6, pages 414 - 418
		- GALON J ET AL., "Type, density, and location of immune cells within human colorectal tumors predict clinical outcome", SCIENCE, (2006), vol. 313, doi:doi:10.1126/SCIENCE.1129139, pages 1960 - 1964, XP002684010 DOI: http://dx.doi.org/10.1126/SCIENCE.1129139
		- GATTINONI L ET AL., "Adoptive immunotherapy for cancer: building on success", NAT. REV. IMMUNOL., (2006), vol. 6, doi:doi:10.1038/nri1842, pages 383 - 393, XP002607145 DOI: http://dx.doi.org/10.1038/nri1842
		- GEBBINK MF ET AL., "Cloning, expression and chromosomal localization of a new putative receptor-like protein tyrosine phosphatase", FEBS LETT., (1991), vol. 290, doi:doi:10.1016/0014-5793(91)81241-Y, pages 123 - 130, XP055083157 DOI: http://dx.doi.org/10.1016/0014-5793(91)81241-Y
		- GNJATIC S ET AL., "Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses", PROC NATL. ACAD. SCI. U. S. A, (2003), vol. 100, pages 8862 - 8867
		- HAMMER J ET AL., "Peptide binding specificity ofHLA-DR4 molecules: correlation with rheumatoid arthritis association", J EXP. MED, (1995), vol. 181, pages 1847 - 1855
		- HANADA K; YEWDELL JW; YANG JC, "Immune recognition of a human renal cancer antigen through post-translational protein splicing", NATURE, (2004), vol. 427, pages 252 - 256
		- HARROCH S ET AL., "A critical role for the protein tyrosine phosphatase receptor type Z in functional recovery from demyelinating lesions", NAT. GENET., (2002), vol. 32, doi:doi:10.1038/ng1004, pages 411 - 414, XP002329234 DOI: http://dx.doi.org/10.1038/ng1004
		- HEIMBERGER AB ET AL., "Tumor-specific peptide vaccination in newly- diagnosed patients with GBM", JOURNAL OF CLINICAL ONCOLOGY, 2006 ASCO ANNUAL MEETING PROCEEDINGS PART I, (20060620), vol. 24, no. 18, page 2529
		- HILL ET AL., J. EXP. MED., (1995), vol. 181, pages 2221 - 2228
		- JEROME ET AL., J. IMMUNOL., (1993), vol. 151, pages 1654 - 1662
		- JOCHMUS ET AL., J. GEN. VIROL., (1997), vol. 78, pages 1689 - 1695
		- JUNG G; LEDBETTER JA; MULLER-EBERHARD HJ, "Induction of cytotoxicity in resting human T lymphocytes bound to tumor cells by antibody heteroconjugates", PROC NATL ACAD SCI U S A, (1987), vol. 84, pages 4611 - 4615
		- KAPLAN R ET AL., "Cloning of three human tyrosine phosphatases reveals a multigene family of receptor-linked protein-tyrosine-phosphatases expressed in brain", PROC NATL. ACAD. SCI. U. S. A, (1990), vol. 87, doi:doi:10.1073/pnas.87.18.7000, pages 7000 - 7004, XP002953383 DOI: http://dx.doi.org/10.1073/pnas.87.18.7000
		- KARRE; LJUNGGREN, J. EXP. MED., (1985), vol. 162, page 1745
		- KAWAKAMI ET AL., J. IMMUNOL., (1992), vol. 148, pages 638 - 643
		- KENNEDY RC ET AL., "CD4+ T lymphocytes play a critical role in antibody production and tumor immunity against simian virus 40 large tumor antigen", CANCER RES., (2003), vol. 63, pages 1040 - 1045
	- KOBAYASHI H ET AL., "Identification of an antigenic epitope for helper T lymphocytes from carcinoembryonic antigen", CLIN CANCER RES., (2002), vol. 8, pages 3219 - 3225
	- ARTHUR M. KRIEG, "Therapeutic potential of Toll-like receptor 9 activation", NATURE REVIEWS, DRUG DISCOVERY, (2006), vol. 5, pages 471 - 484
	- KRUEGER NX; STREULI M; SAITO H, "Structural diversity and evolution of human receptor-like protein tyrosine phosphatases", EMBO J, (1990), vol. 9, pages 3241 - 3252, XP002034366
	- LEMMEL C ET AL., "Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling", NAT. BIOTECHNOL., (2004), vol. 22, doi:doi:10.1038/nbt947, pages 450 - 454, XP002359085 DOI: http://dx.doi.org/10.1038/nbt947
	- LEVY JB ET AL., "The cloning of a receptor-type protein tyrosine phosphatase expressed in the central nervous system", J BIOL. CHEM., (1993), vol. 268, pages 10573 - 10581
	- LONGENECKER ET AL., ANN. NY ACAD. SCI., (1993), vol. 690, pages 276 - 291
	- LU ET AL., J. ORG. CHEM., (1981), vol. 46, page 3433
	- LU KV ET AL., "Differential induction of glioblastoma migration and growth by two forms of pleiotrophin", J BIOL CHEM., (2005), vol. 280, doi:doi:10.1074/JBC.M502614200, pages 26953 - 26964, XP002514091 DOI: http://dx.doi.org/10.1074/JBC.M502614200
	- MACDONALD DR, "Temozolomide for recurrent high-grade glioma", SEMIN. ONCOL, (2001), vol. 28, pages 3 - 12
	- MACH B ET AL., "Regulation of MHC class II genes: lessons from a disease", ANNU. REV. IMMUNOL., (1996), vol. 14, pages 301 - 331
	- A MAHDAVI; BJ MONK, "Recent advances in human papillomavirus vaccines", CURR ONCOL REP, (2006), vol. 6, pages 465 - 472
	- MALCHEREK G ET AL., "Analysis of allele-specific contact sites of natural HLA-DR17 ligands", J IMMUNOL., (1994), vol. 153, pages 1141 - 1149, XP002025352
	- MANICI S ET AL., "Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11", J EXP. MED, (1999), vol. 189, doi:doi:10.1084/jem.189.5.871, pages 871 - 876, XP002165456 DOI: http://dx.doi.org/10.1084/jem.189.5.871
	- MULHOLLAND PJ ET AL., "Genomic profiling-identifies discrete deletions associated with translocations in glioblastoma multiforme", CELL CYCLE, (2006), vol. 5, pages 783 - 791, XP002484251
	- STRUBIN, M.; MACH, B.; LONG, E.O., "The complete sequence of the mRNA for the HLA-DR-associated invariant chain reveals a polypeptide with an unusual transmembrane polarity", EMBO J., (1984), vol. 3, no. 4, pages 869 - 872
	- NAPOLITANO M ET AL., "Treatment of supratentorial glioblastoma multiforme with radiotherapy and a combination of BCNU and tamoxifen: a phase II study", J NEUROONCOL., (1999), vol. 45, pages 229 - 235
	- NIEDER C; GROSU AL; MOLLS M, "A comparison of treatment results for recurrent malignant gliomas", CANCER TREAT. REV., (2000), vol. 26, doi:doi:10.1053/ctrv.2000.0191, pages 397 - 409, XP001071041 DOI: http://dx.doi.org/10.1053/ctrv.2000.0191
	- NOVELLINO L; CASTELLI C; PARMIANI G, "A listing of human tumor antigens recognized by T cells: March 2004 update", CANCER IMMUNOL. IMMUNOTHER., (2005), vol. 54, doi:doi:10.1007/s00262-004-0560-6, pages 187 - 207, XP019333092 DOI: http://dx.doi.org/10.1007/s00262-004-0560-6
	- PASCOLO S., "Vaccination with messenger RNA", METHODS MOL MED, (2006), vol. 127, pages 23 - 40, XP009117840
	- PEOPLES ET AL., PROC. NATL. ACAD. SCI. USA, (1995), vol. 92, pages 432 - 436
	- PEREZ-PINERA P ET AL., "The receptor protein tyrosine phosphatase (RPTP)beta/zeta is expressed in different subtypes of human breast cancer", BIOCHEM. BIOPHYS. RES. COMMUN., (2007), vol. 362, pages 5 - 10
	- PLEBANSKI ET AL., EUR. J. IMMUNOL., (1995), vol. 25, pages 1783 - 1787
	- PORTA ET AL., VIROLOGY, (1994), vol. 202, pages 449 - 955
	- PRADOS MD; LEVIN V, "Biology and treatment of malignant glioma", SEMIN. ONCOL, (2000), vol. 27, pages 1 - 10
	- QIN Z; BLANKENSTEIN T, "CD4+ T cell--mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells", IMMUNITY., (2000), vol. 12, pages 677 - 686
	- QIN Z ET AL., "A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells", CANCER RES., (2003), vol. 63, pages 4095 - 4100
	- RAMMENSEE HG ET AL., "SYFPEITHI: database for MHC ligands and peptide motifs", IMMUNOGENETICS, (1999), vol. 50, doi:doi:10.1007/s002510050595, pages 213 - 219, XP002254433 DOI: http://dx.doi.org/10.1007/s002510050595
	- RINI BI ET AL., "Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (Provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy", CANCER., (2006), vol. 107, no. 1, pages 67 - 74
	- ROSENBERG SA ET AL., "A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone", N. ENGL. J. MED., (1987), vol. 316, pages 889 - 897, XP001118518
	- ROSENBERG SA ET AL., "Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report", N. ENGL. J MED, (1988), vol. 319, pages 1676 - 1680, XP009032797
	- ROTH W; WELLER M, "Chemotherapy and immunotherapy of malignant glioma: molecular mechanisms and clinical perspectives", CELL MOL. LIFE SCI., (1999), vol. 56, pages 481 - 506
	- SABLOTZKI A ET AL., "Dysregulation of immune response following neurosurgical operations", ACTA ANAESTHESIOL. SCAND., (2000), vol. 44, pages 82 - 87
	- SAIKI ET AL., SCIENCE, (1988), vol. 239, pages 487 - 491
	- SMALL EJ ET AL., "Placebo-controlled phase 3 trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer", J CLIN ONCOL., (2006), vol. 24, no. 19, pages 3089 - 3094
	- SCHUBERT U ET AL., "Rapid degradation of a large fraction of newly synthesized proteins by proteasomes", NATURE, (2000), vol. 404, pages 770 - 774
	- SEEGER,F.H. ET AL., "The HLA-A*6601 peptide motif: prediction by pocket structure and verification by peptide analysis.", IMMUNOGENETICS, (1999), vol. 49, pages 571 - 576
	- SHEDLOCK DJ; SHEN H, "Requirement for CD4 T cell help in generating functional CD8 T cell memory", SCIENCE, (2003), vol. 300, pages 337 - 339
	- SINGH-JASUJA H; EMMERICH NP; RAMMENSEE HG, "The Tubingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy", CANCER IMMUNOL. IMMUNOTHER., (2004), vol. 53, pages 187 - 195
	- M. STAEHLER ET AL., "An open label study to evaluate the safety and immunogenicity of the peptide based cancer vaccine IMA901", ASCO, (2007), vol. 3017
	- R. STAN; JD WOLCHOK; AD COHEN, "DNA vaccines against cancer", HEMATOL ONCOL CLIN NORTH AM, (2006), vol. 3, pages 613 - 636
	- SUN JC; BEVAN MJ, "Defective CD8 T cell memory following acute infection without CD4 T cell help", SCIENCE, (2003), vol. 300, pages 339 - 342
	- SYLVESTER-HVID C ET AL., "Establishment of a quantitative ELISA capable of determining peptide - MHC class I interaction", TISSUE ANTIGENS, (2002), vol. 59, doi:doi:10.1034/j.1399-0039.2002.590402.x, pages 251 - 258, XP055006262 DOI: http://dx.doi.org/10.1034/j.1399-0039.2002.590402.x
	- TOMPKINS SM ET AL., "A europium fluoroimmunoassay for measuring binding of antigen to class II MHC glycoproteins", J IMMUNOL. METHODS, (1993), vol. 163, doi:doi:10.1016/0022-1759(93)90124-P, pages 209 - 216, XP023974966 DOI: http://dx.doi.org/10.1016/0022-1759(93)90124-P
	- VAN DER BRUGGEN P ET AL., "A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma", SCIENCE, (1991), vol. 254, doi:doi:10.1126/science.1840703, pages 1643 - 1647, XP002628352 DOI: http://dx.doi.org/10.1126/science.1840703
	- VIGNERON N ET AL., "An antigenic peptide produced by peptide splicing in the proteasome", SCIENCE, (2004), vol. 304, doi:doi:10.1126/science.1095522, pages 587 - 590, XP002590787 DOI: http://dx.doi.org/10.1126/science.1095522
	- VOGT AB ET AL., "Ligand motifs ofHLA-DRB50101 and DRB11501 molecules delineated from self-peptides", J IMMUNOL., (1994), vol. 153, pages 1665 - 1673, XP002245824
	- WALTER S ET AL., "Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres", J. IMMUNOL., (2003), vol. 171, pages 4974 - 4978
	- WANG JC; LIVINGSTONE AM, "Cutting edge: CD4+ T cell help can be essential for primary CD8+ T cell responses in vivo", J IMMUNOL., (2003), vol. 171, pages 6339 - 6343
	- WANG V ET AL., "Differential gene up- regulation by hypoxia-inducible factor-lalpha and hypoxia-inducible factor-2alpha in HEK293T cells", CANCER RES., (2005), vol. 65, pages 3299 - 3306
	- WEINSCHENK T ET AL., "Integrated functional genomics approach for the design of patient-individual antitumor vaccines", CANCER RES., (2002), vol. 62, pages 5818 - 5827
	- WU CW ET AL., "Protein tyrosine-phosphatase expression profiling in gastric cancer tissues", CANCER LETT., (2006), vol. 242, doi:doi:10.1016/j.canlet.2005.10.046, pages 95 - 103, XP025021733 DOI: http://dx.doi.org/10.1016/j.canlet.2005.10.046
	- YEE C ET AL., "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells", PROC. NATL. ACAD. SCI. U. S. A, (2002), vol. 99, doi:doi:10.1073/PNAS.242600099, pages 16168 - 16173, XP002505178 DOI: http://dx.doi.org/10.1073/PNAS.242600099
	- ZAREMBA S ET AL., "Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen", CANCER RES., (1997), vol. 57, pages 4570 - 4577, XP002096107
	- ZEH HJ, III ET AL., "High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy", J IMMUNOL., (1999), vol. 162, pages 989 - 994, XP002133806

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p